For research use only. We do not sell to patients.
Ionizable lipids / AMG1541
AMG1541 chemical structure
Product imageResearch use only
CAT. NO. DC67558Featured

AMG1541

Research highlights
Defined 35:16:46.5:2.5 molar-percent formulationReported N/P approximately 11.4 at a 10:1 ionizable-lipid:RNA mass ratioInfluenza antibody dose-sparing in mice; not a clinical protection result

Pack size & price

USD
Supporting components
DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$550
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

AMG-1541 is a degradable cyclic amino alcohol ionizable lipid optimized for mRNA vaccine delivery using lipid nanoparticles (LNPs). Formulated typically with DOPE, cholesterol, and PEG-lipids, AMG 1541 LNPs have a diameter of ~85 nm, PDI of 0.107, and encapsulation efficiency of 67%, ensuring stability and efficient mRNA delivery. In vitro, it outperforms benchmarks like SM-102, showing enhanced transfection in cells such as C2C12 and PBMCs. In vivo, intramuscular administration in mice results in robust protein expression within 6 hours and induces potent immune responses, including high antibody titers and Th1-biased T-cell activation, with minimal inflammation. Mechanistically, its β-hydroxyl groups form hydrogen bonds with mRNA phosphate backbones, facilitating endosomal escape. AMG1541 degrades rapidly under enzymatic conditions, reducing long-term toxicity, and is effective for vaccines targeting pathogens like influenza and SARS-CoV-2, making it a promising candidate for clinical applications.

CAS No.Not available
Chemical NameAMG1541
SynonymsAMG-1541，AMG 1541
SMILESCCCCCC/C=C\CCCC(=O)OCC(O)CN1CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CC1
FormulaC102H186O18N6
M.Wt1,783.38
PurityELSD-HPLC>95%
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
PublicationRudra A, Gupta A, Reed K, et al. Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines. Nature Nanotechnology. 2025;20:1831–1842.

Literature-reported formulation composition

Componentmol%Role
AMG154135Ionizable lipid
DOPE16Helper phospholipid
Cholesterol46.5Sterol
DMG-PEG20002.5PEG lipid
Reported total100Source values retained

Formulation weight calculator

The cited formulation and available component molecular weights are pre-filled. Enter the exact molecular weight for any substituted material before calculating.

Calculators use the listed value 1783.38 g/mol, based on the neutral monoisotopic mass. The calculated average formula mass is 1784.63 g/mol; the MW inputs are editable to match your material and calculation convention.

The 4 reported lipid components total 100 mol%.
ComponentMolecular weight (g/mol)Literature molar ratio
AMG1541
DOPE
Cholesterol
DMG-PEG2000
Calculated component requirements
ComponentNormalized mol%Amount (µmol)Required weight (mg)
Total100.000%——

Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

11.4
10:1 w/w
mRNA 133 ng/µL in 10 mM citrate, pH 3.0; helper lipid ethanol stocks 10 mg/mL and ionizable lipid stock 40 mg/mL.
FLuc reporter mRNA or influenza HA mRNA, as individually specified below.
Intramuscular
All doses use total RNA, not encapsulated RNA. Reporter comparison: 1 µg. Vaccination: 0.01–1 µg per dose on days 0 and 21.
Mice, 6–8 weeks at study start; BALB/cJ or C57BL/6J, sex as stated for each assay.
Herringbone microfluidic mixing; aqueous:ethanol phase 3:1 v/v; total flow 1.2 mL/min.

Literature-reported performance for the cited formulation

Literature-reportedApproximately 3.5-fold versus SM-102 and 1.7-fold versus cKK-E12BALB/cJ mice · FLuc mRNA · 1 µg · IM · 6 h · SM-102/DSPC and cKK-E12 reference formulationsThe figure caption and source table contain inconsistent replicate counts. Fold estimates are those reported by the authors; no reconciled sample size or recalculated significance is asserted.Main Fig.2c and Results; Source Data Fig.2, B14:F21
Literature-reportedAuthors report comparable binding and HAI antibody responses at 0.01 µg AMG1541 versus 1 µg SM-102Female BALB/cJ mice; n=5 per group · HA mRNA, A/Tasmania/503/2020 (H3N2) · 0.01, 0.1 or 1 µg per dose · IM, quadriceps · Prime day 0, boost day 21; serum day 35 · SM-102/DSPC referenceThis is a 100-fold dose comparison on antibody endpoints. No viral-challenge protection or clinical efficacy is established by this comparison.Main Fig.3f, Extended Data Fig.4b; Source Data Fig.3, C30:G32 and I30:M32
Literature-reported15.8-fold (male BALB/cJ), 6.8-fold (female BALB/cJ), 5.8-fold (female C57BL/6J) versus SM-102Strain and sex as stated; n=5 per group · Influenza HA mRNA · 1 µg per dose · IM · Days 0 and 21 dosing; day 35 assay · SM-102/DSPC referenceSeparate strain/sex comparisons; no pooled estimate or universal Th1 bias is established.Main Results, vaccine immunogenicity; Fig.3b,e
Literature-reportedMost measured cytokines were comparable between formulations; female IL-2 was approximately fivefold higher with AMG1541Male and female BALB/cJ mice · Influenza HA mRNA · 1 µg per dose · IM · 6 h after boost · SM-102/DSPC referenceA limited acute reactogenicity readout, not evidence of comprehensive or clinical safety.Main Fig.3h; Source Data Fig.3, C70:G70 and I70:M70

Additional reported findings

Formulation-dependent comparison

AMG1541/DSPC and SM-102/DOPE cross-formulations were separately tested. Delivery differences cannot be attributed solely to the ionizable lipid.

Helper-lipid identity is a variable in the comparison · SI Fig.10 and formulation discussion, PDF pp.14–15
Representative LNP characterization

Diameter 85 nm; PDI 0.107; RNA encapsulation 67%. Replicate count and SD are not supplied in this table.

AMG1541-DOPE-IM formulation; representative values · SI Table 3, PDF p.18 / printed p.17
Apparent LNP pKa

Approximately 6.5 by TNS assay at 25 °C; this is not the intrinsic pKa of the isolated lipid.

Formulated LNP assay · Main Results and Methods, Apparent pKa
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetRudra A, Gupta A, Reed K, et al. Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines. Nature Nanotechnology. 2025;20:1831–1842. DOI: 10.1038/s41565-025-02044-6
Main Methods and SI Table 1 support the formulation. N/P is approximately 11.4 as reported by the authors; 10:1 is the ionizable-lipid:mRNA mass ratio. Assay-specific conditions and source locations are listed with each result.

Publisher record · Public author manuscript

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Calculators use the listed value 1783.38 g/mol, based on the neutral monoisotopic mass. The calculated average formula mass is 1784.63 g/mol; the MW inputs are editable to match your material and calculation convention.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg5.6073 mL1.1215 mL560.73 μL
25 mg14.0183 mL2.8037 mL1.4018 mL
50 mg28.0366 mL5.6073 mL2.8037 mL
100 mg56.0733 mL11.2147 mL5.6073 mL
250 mg140.1832 mL28.0366 mL14.0183 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.